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Abstract
Background: Overexpression of α-synuclein (SNCA) in families with multiplication mutations
causes parkinsonism and subsequent dementia, characterized by diffuse Lewy Body disease post-
mortem. Genetic variability in SNCA contributes to risk of idiopathic Parkinson's disease (PD),
possibly as a result of overexpression. SNCA downregulation is therefore a valid therapeutic target
for PD.
Results: We have identified human and murine-specific siRNA molecules which reduce SNCA in
vitro. As a proof of concept, we demonstrate that direct infusion of chemically modified (naked),
murine-specific siRNA into the hippocampus significantly reduces SNCA levels. Reduction of SNCA
in the hippocampus and cortex persists for a minimum of 1 week post-infusion with recovery
nearing control levels by 3 weeks post-infusion.
Conclusion: We have developed naked gene-specific siRNAs that silence expression of SNCA in
vivo. This approach may prove beneficial toward our understanding of the endogenous functional
equilibrium of SNCA, its role in disease, and eventually as a therapeutic strategy for α-
synucleinopathies resulting from SNCA overexpression.
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Background
The importance of α-synuclein in the pathogenesis of Par-
kinson's disease (PD) initially emerged in 1997 when
Polymeropoulos and colleagues reported that a missense
A53T mutation in the α-synuclein gene (SNCA) causes
familial parkinsonism in four seemingly unrelated kin-
dreds [1]. Subsequently, SNCA A30P and E46K missense
mutations were found to cause familial Lewy Body par-
kinsonism [2,3]. The importance of the α-synuclein pro-
tein (non-amyloid component precursor; NACP) was
confirmed through its recognition as a major component
of both Lewy bodies, the pathological hallmark of PD and
dementia with Lewy bodies (DLB), and of glial cytoplas-
mic inclusions in multiple system atrophy (MSA) [4].
In addition to missense mutations, multiplication of the
normal SNCA locus can cause familial PD. Singleton et al.
first reported genomic triplication of the SNCA locus in
affected family members with early onset, parkinsonism,
with subsequent cognitive dysfunction [5]. Post-mortem
exam revealed profound neuronal loss in the substantia
nigra (SN) and widespread Lewy pathology from the cor-
tex to the basal ganglia [6,7]. Additional de novo SNCA
duplications and triplications have since been reported in
French, Japanese, Korean and Swedish-American families
[8-14]. Functionally, SNCA  multiplications result in a
copy-number related increase in both α-synuclein RNA
and protein [8,15], and disease onset and severity are
associated with gene dosage [11]. Taken together, this pro-
vides compelling evidence that SNCA overexpression can
result in Lewy body parkinsonism and dementia.
Although SNCA multiplication remains a rare cause of
inherited PD, common genetic variability in the SNCA
locus is a risk factor for idiopathic PD [16-18]. The effects
may be mediated by elevated mRNA/protein expression
[8,15,19,20]. Hence therapy aimed at reducing SNCA
expression levels may provide therapeutic benefit for
patients with either familial or idiopathic PD.
The use of double-stranded RNAs for the silencing of
genes was first accomplished in nematodes [21]. Mole-
cules of 21 and 22 nucleotides had the most activity in
Drosophila, and these reagents were named short interfer-
ing (si)RNAs [22]. siRNA induces the formation of an
RNA-induced silencing complex (RISC) which acts as an
endonuclease on target RNA [23], yielding a powerful tool
which can be used to reduce expression of specific genes.
To exploit the therapeutic potential of siRNA, we devel-
oped naked siRNA molecules against SNCA that are resist-
ant to endo- and exonuclease activity in serum and yield
species-specific reduction of SNCA in vitro. We then
injected them into the Cornu Ammonis (CA1) of the hip-
pocampus of mice and demonstrated a reduction in
SNCA mRNA levels by quantitative reverse transcription-
polymerase chain reaction (RT-PCR) and in situ hybridiza-
tion throughout the hippocampus and cortex. Addition-
ally, we have demonstrated that α-synuclein protein
expression in these same cells is qualitatively reduced.
This protocol will be invaluable for improving our under-
standing of the in vivo dynamics of SNCA, assessing the
impact of SNCA silencing in the pathogenesis of animal
models of PD, and perhaps may hold promise as a future
neuroprotective therapy for PD in humans.
Methods
In vitro characterization of siRNA
Detailed method for in vitro studies including siRNA syn-
thesis, cell culture and transfection conditions, fluores-
cent microscopy, RNA and protein analysis and siRNA
serum stability analysis are detailed in the additional files
section.
In vivo delivery of siRNA
All rodent procedures were approved by the Mayo Clinic
Institutional Animal Care and Use Committee (IACUC),
were in accordance with the National Institute of Health
Guide for the Care and Use of Laboratory Animals (NIH
Publications No. 80-23, revised 1996) and were per-
formed under the supervision of an institutional veteri-
narian. Mice were allowed unrestricted access to food and
water and were supplemented with gelatin containing (32
mg/ml) acetaminophen from 24 hours prior to surgery
until 48 hours post-surgery to minimize pain. The day
prior to surgery, Alzet osmotic pumps (model 1002,
Durect, Inc., Cupertino, CA) were filled to capacity with
siRNA against SNCA or luciferase at a concentration of 2
mM in phosphate buffered saline (PBS). Pumps contain-
ing only PBS were prepared for an additional control
group. Mice were anaesthetized with tribromoethanol
(200 mg/kg) and stereotaxic surgery was performed to
implant a 3 mm cannula at -1.5 mm posterior and -2.0
mm lateral from bregma and 2.5 mm deep by the inser-
tion of 2 spacers (0.25 mm each) to target the CA1 of the
right hippocampus in each 2-month old C57BL/6 female
mice [24]. Cannulae were secured to the skull using Loc-
tite adhesive (Durect, Inc., Cupertino, CA). Mice were
allowed to recover from the anesthesia under a heat lamp.
SNCA siRNA, luciferase siRNA or PBS was infused at a rate
of 0.25 μl/hour over 15 days using Alzet osmotic pumps
attached to 3 mm brain infusion cannulae (Alzet brain
infusion kit 3, Durect, Inc., Cupertino, CA; http://
www.alzet.com/products/brainkits.php). Following 15
days infusion, brain tissue was harvested from the 2 week
(2 W) cohorts while cannulae were removed on day 15 in
cohorts that were allowed to age one week (2 W-1 W), two
weeks (2 W-2 W) or three weeks (2 W–3 W) after the ces-
sation of infusion. At harvest, osmotic pumps were recov-
ered. Mice in which the pump had failed or in which the
tubing had become disconnected from the pump wereMolecular Neurodegeneration 2008, 3:19 http://www.molecularneurodegeneration.com/content/3/1/19
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included in study groups and in statistical analysis; how-
ever, for graphical purposes, the data points for these mice
were denoted by distinct symbols when compared to mice
in which the pumps were intact and functional. Experi-
ments detailed in Figures 1, 2 and 3 were performed on
independent cohorts of mice.
Taqman qRT-PCR analysis of SNCA levels
For Taqman analysis, the hippocampus was rapidly
removed from each hemisphere of the brain and snap-fro-
zen on dry ice in separate tubes. In each case, the right hip-
pocampus represented the injected side (SNCA  siRNA,
luciferase siRNA, or PBS) and the left hippocampus was
utilized as an untreated control. RNA was extracted by
phenol extraction using the TRIzol Reagent (Invitrogen;
Carlsbad, CA) with the manufacturer's standard protocol.
cDNA was then synthesized using the High Capacity
cDNA Archive Kit (Applied Biosystems; Foster City, CA).
The following probes were purchased from ABI: GAPDH
(Mm99999915_g1), HPRT (Mm01545399_m1), SNCA
(Mm00447333_m1), and SNCB  (Mm00504325_m1).
Quantitative RT-PCR was performed on an ABI 7900 HT
using a 384 well plate with quadruple sample replicates.
Results were analyzed using SDS v.2.2 software and the
expression data was normalized to mouse GAPDH and
HPRT. Resulting graphs and data were generated using
GraphPad Prism v.4 software (GraphPad Software Inc., La
Jolla, CA).
In situ analysis of SNCA and SNCB levels
To ensure sampling consistency, the brain was placed in a
tissue matrix and the region anterior and posterior to the
qRT-PCR analysis of SNCA expression following in vivo RNAi Figure 1
qRT-PCR analysis of SNCA expression following in vivo RNAi.SNCA siRNA (syn-siRNA), luciferase siRNA (luc-siRNA), 
or PBS was infused into the right CA1. qRT-PCR was used to determine expression of SNCA following RNAi in treated right 
side compared to the untreated contralateral side (R:L ratio). SNCA siRNA had a statistically significant decrease of SNCA 
expression in the right compared to the left side of the brain, and R:L ratios were decreased when compared to controls (vs 
PBS, p = 0.036; vs. luciferase, p = 0.004). Horizontal lines show medians. Open circles indicate mice in which the cannula was 
disconnected during treatment or did not function.Molecular Neurodegeneration 2008, 3:19 http://www.molecularneurodegeneration.com/content/3/1/19
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RNA and protein analysis of α-synuclein expression following in vivo SNCA siRNA treatment Figure 2
RNA and protein analysis of α-synuclein expression following in vivo SNCA siRNA treatment. The right CA1 was 
infused with either PBS, siRNA to luciferase, or siRNA against our SNCA target. A typical SNCA in situ from an animal treated 
with (A) PBS or (B) SNCA siRNA on the right side compared to the uninjected left sides. While the cannula tract was evident in 
the right hippocampi of the infused mice (* in C and F), regardless of treatment group, (C) immunostaining for α-synuclein 
demonstrates considerable knockdown of protein expression (arrowhead) in the hippocampus when the uninjected control 
side is compared to the SNCA siRNA-treated side, also shown in higher magnification (D, E), respectively. (F) Inflammatory 
changes, as shown by Iba-1 immunostaining for microgliosis, were minimal around the infusion site. Sample brain in (F) showed 
the highest degree of damage from infusion, in this case from SNCA siRNA.
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Silencing of SNCA is resilient and target-specific Figure 3
Silencing of SNCA is resilient and target-specific.SNCA and SNCB expression was assessed by in situ hybridization follow-
ing extended timecourse of in vivo SNCA siRNA treatment. Qualitative densitometric analysis was performed on mice treated 
with SNCA siRNA on the right side of the brain and a ratio showing either SNCA or SNCB expression in the treated (R) and 
untreated (L) brain was calculated and plotted for each animal within a group. The knockdown of SNCA expression (black cir-
cle) persists in the (A) CA1 and the (B) cortex two weeks after cannula removal with SNCA approaching normal levels by three 
weeks post-infusion. The closed triangle indicates SNCA levels in a mouse in which the cannula was loose at the end of the 
study. Non-specific silencing of SNCB (open circle) was not observed at any timepoint.
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hippocampus was removed using a flat blade. The result-
ing three brain segments were snap frozen on dry ice and
stored at -80°C until use. 15 μm thick frozen sections
were cut on a cryostat at -18°C throughout the entire hip-
pocampus and air dried for 20 minutes before freezing at
-80°C. Frozen sections were removed on dry ice and dried
quickly on a slide warmer at 55°C, fixed in 4% parafor-
maldehyde in 0.1 M Sorensen's Phosphate buffer for 20
minutes, washed twice in PBS and dehydrated in ascend-
ing alcohols. Hybridization was performed at 37°C over-
night in a moist chamber, with approximately 0.02 ng of
[α-33P] dATP (Perkin Elmer, Waltham, MA, USA) 3' end
labeled probe per 1 μl of hybridization buffer (4× sodium
chloride/sodium citrate (SSC), 1× Denhardt's solution,
50% (w/v) de-ionised formamide, 10% (w/v) dextran sul-
phate, 200 mg/μl herring sperm DNA). The SNCA probe
(5'GGTCTTCTCAGCCACTGTTGTCACTCCATGAAC-
CAC'3) was designed to exon 3. The beta-synuclein (SNCB)
probe was designed to the 3' untranslated region (UTR)
(5'CAGACAGATTGGCTTTATTCATGGACACACT-
GGG'3). Specific activity of the probe was at least 1 × 108
counts per minute (cpm)/μg, and after dilution in hybrid-
ization buffer corresponded to ~1 × 104 cpm/μl. Control
hybridizations contained a 50-fold molar excess of unla-
belled probe to determine non-specific signal. Slides were
washed in 1× SSC at room temperature (RT) to remove
excess hybridization buffer; three times at 55°C for 30
minutes per wash and at RT for 60 minutes. Slides were
then dipped for 30 seconds in 70% (v/v) ethanol/300 mM
ammonium acetate, then for 30 seconds in absolute alco-
hol, air dried and co-exposed with 12C microscale stand-
ards (Amersham, Piscataway, NJ) to Biomax MS film
(Kodak, Rochester, NY) for 7–10 days.
Densitometric analysis of the images was performed using
a micro computing imaging device and MCID Elite v.7
software (MCID, Imaging Research Inc., Ontario, Can-
ada). Sections which were anatomically asymmetrical,
damaged or in which the hippocampus was not visible
were not included in the analysis. Five matching areas for
analysis were outlined on the left and right hemispheres
of each section: cortex including retrosplenial agranular
cortex, primary and secondary motor cortex; hippocam-
pus CA1; CA2; CA3; and dentate gyrus (DG) including
polymorph layer DG. Optical density readings were cali-
brated to the 12C microscale standards to give radioactiv-
ity quantities in nCi/μg.  SNCA  densitometry was
measured in cortex, CA1, CA2, CA3, and dentate gyrus of
the treated (right) side of the brain and compared to cor-
responding regions in the untreated (left) side in two to
four sections per animal.
Immunohistochemistry
5  μm paraffin sections were de-waxed, hydrated and
washed in PBS. Endogenous peroxidases were blocked in
0.3% hydrogen peroxide in PBS. To allow epitope
unmasking, sections stained for activated microglia with
Iba-1 were steamed in distilled water for 30 minutes.
Unmasking was not required for α-synuclein. Non-spe-
cific sites were blocked with 5% non-fat milk in PBS for 30
minutes. Sections were then incubated for 1 hour at RT
with a mouse IgG1 anti-α-synuclein antibody (1:500 dilu-
tion, clone 42, BD Biosciences, San Jose, CA) or rabbit
Iba-1 antibody (1:1000 dilution, Wako Chemicals USA,
Richmond, VA) in 5% non-fat milk. Control slides were
set up without primary antibody. Sections were then
washed in PBS twice for five minutes and then incubated
with anti-mouse biotinylated secondary antibody (Vector
Laboratories, Burlingame, CA, USA). After washing, sec-
tions were then incubated with Vectastain ABC® reagent in
PBS according to the manufacturer's instructions. Signal
was visualized with DAB (3',3' diaminobenzidine, Vector
Laboratories).
Statistical analysis
Statistical analysis for in vitro studies utilized the t-test to
compare groups; Welch's modified t-test was used when
variances differed. Numerical variables were summarized
with the sample median, 25th percentile, and 75th percen-
tile. The Wilcoxon signed rank sum test was used to test
whether the median right/left (R:L) ratio of SNCA expres-
sion from quantitative RT-PCR differed from 1. The Wil-
coxon rank sum test was used to compare qRT-PCR SNCA
expression between siRNA and control mice groups; it was
also used to compare SNCA  densitometry R:L ratio
between groups of mice. Graphical exploration was used
to investigate trends in SNCA  densitometry R:L brain
region ratio over different timepoints. Statistical signifi-
cance was determined at the 5% level.
Results and discussion
Screening for active siRNAs in vitro
We initially designed nine siRNAs (Mayo 1–9) which are
complementary to the SNCA  transcript in the coding
region and the 3'-UTR region (Additional file 1). These
siRNAs were screened for their ability to silence the
expression of a transiently co-transfected enhanced green
fluorescent protein-human SNCA  fusion construct
(pEGFP-NACP) in BE(2)-M17 human neuroblastoma
cells. Controls included siRNAMr, specific for the
enhanced green fluorescence protein (EGFP) portion of
the conjugate, and cells transfected with plasmid DNA in
the absence of siRNA. Mayo 2, 7 and 8 were found to pro-
duce ≥ 89% silencing (Additional file 2). The controls did
not display significant silencing (<43%). In the absence of
plasmid co-transfection, quantitative RT-PCR showed that
the endogenous SNCA mRNA transcript was reduced by
89% for Mayo 2, 52% for Mayo 7 and 67% for Mayo 8
(Additional file 3). In immunoblots endogenous α-synu-
clein protein showed a 45%, 55% or 53% knockdown forMolecular Neurodegeneration 2008, 3:19 http://www.molecularneurodegeneration.com/content/3/1/19
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Mayo 2, 7 and 8 respectively (Additional file 3). As
opposed to Mayo 7 and Mayo 8, Mayo 2 siRNA diverged
from SNCB  sequence at only four bases; therefore, we
demonstrated that Mayo 2 did not silence the closely
related endogenous SNCB transcript (Additional file 4).
To further test the species specificity of Mayo 2, 7 and 8,
co-transfection of siRNAs was performed with either
human or murine SNCA-pEGFP plasmid. Silencing of
human SNCA versus murine SNCA was 74% and 79%
respectively for Mayo2, whereas Mayo 7 and 8 were more
human specific (85% human and 47% mouse for Mayo 7
and 73% human and 7% mouse for Mayo8. (Additional
file 4)
Since siRNAs can be readily degraded in vivo, assays in
human serum were performed using modified Mayo 7
and 8 siRNAs (containing either phosphothiorate link-
ages or 2'-O-methyl substitutions) and enhanced stability
was observed (Additional file 5). Modified siRNAs were
re-tested for silencing of endogenous SNCA transcript and
were found to have maintained their efficacy. A modified
version of human specific Mayo8 (Mayo8S2) was selected
as the best candidate based on its stability and silencing
properties but for in vivo testing in mice it was necessary
to modify it to complement murine SNCA mRNA
(Mayo8S2M). In vitro testing with either human or
murine pEGFP plasmid followed by immunoblot analy-
sis, demonstrated 97% silencing of the murine α-synu-
clein protein and only 23% of the human α-synuclein
protein (Additional file 6).
Specific in vivo knockdown of murine SNCA
In order to test the ability of naked siRNA to reduce SNCA
expression in vivo, we identified the hippocampus and the
cortex as having the highest expression of SNCA in the
murine brain (data not shown). We subsequently chose to
target siRNA against SNCA expression in the hippocam-
pus to decrease variability in our measurements that could
be introduced when dissecting out smaller, less defined
structures. We delivered Mayo8S2M siRNA against
murine SNCA, siRNA against luciferase (luc), or PBS into
the right CA1 of the hippocampi of wild-type C57BL6
female mice. Infusions were performed on these inbred
female mice to reduce variability that can be introduced
by combining genders or by having genetically heteroge-
neous backgrounds. Continuous infusion of the siRNA or
PBS solutions was performed over a period of 15 days
with Alzet mini pumps connected to cannulae which were
surgically implanted into the right CA1. After 15 days, two
pumps containing the SNCA siRNA and three pumps con-
taining the luc siRNA had disconnected. These mice, rep-
resented by open circles, are included in the data analysis
in Figure 1. The left CA1 was not injected and was there-
fore utilized for an untreated control. Hippocampal infu-
sion of the Mayo8S2M siRNA resulted in significant
knockdown of SNCA when assessed by Taqman quantita-
tive real-time PCR. Normalization was performed against
HPRT and GAPDH as endogenous controls. Quantitative
RT-PCR analysis demonstrated that SNCA expression was
significantly decreased in the right (treated) hippocampus
of animals which have received SNCA siRNA when com-
pared to the left (untreated) hippocampus (p = 0.037) as
demonstrated by the R:L ratio of SNCA expression. Addi-
tionally, the SNCA-specific siRNA reduced SNCA expres-
sion when compared to luciferase-siRNA (p = 0.004) and
PBS (p = 0.036) treated control mice (Figure 1).
Although SNCA expression was significantly reduced in
the SNCA siRNA treated hippocampi, we hypothesized
that the efficacy of the siRNA in the brain might be under-
estimated due to partial diffusion of the siRNA into the
contralateral hippocampus. In order to address this issue,
we endeavored to examine the distribution of SNCA
knockdown by in situ hybridization so that the extent of
SNCA reduction could be fully appreciated. Utilizing a
mouse SNCA specific probe, we determined if the knock-
down of SNCA expression extended beyond the CA1 can-
nulation site (Figure 2). SNCA knockdown with SNCA
siRNA was observed an average of 2.67 mm ± 0.57 mm
from the cannula tip. While the cannulation tract was evi-
dent in the infused animals, in general, little damage nor
increase in inflammation (Figure 2C, D, E) was noted at
the site of infusion regardless of treatment group, and no
animals were removed from the study due to hippocam-
pal damage. Figure 2F shows the hippocampus from the
mouse with the most damage at the infusion site. Ratios
were calculated for each animal between the treated
(right) side (SNCA siRNA, luc siRNA, and PBS) and the
untreated (left) side and then compared across each of the
three groups (Table 1). The least reduction in SNCA levels,
shown as a reduction in right (R):left (L) ratio, was
observed in the cortex (71% between PBS and SNCA
siRNA treated animals, p = 0.067), likely reflecting the fact
that the cortex spans from regions adjacent to the infusion
site to regions quite distant from the infusion site and thus
less likely to be affected by the siRNA. Significant reduc-
tions in SNCA levels were observed in the CA1 (66%, p <
0.001), CA2 (59%, p < 0.001), CA3 (77%, p < 0.001), and
dentate gyrus (81%, p = 0.001) when SNCA siRNA treated
animals were compared to PBS treated animals. Similar
results were obtained when SNCA siRNA treated animals
were compared to luc siRNA treated control mice. Reduc-
tion in SNCA levels was confirmed by immunostaining
for murine α-synuclein protein (Figure 2C and 2D). Nota-
bly, α-synuclein levels in the cell bodies of the hippocam-
pus were decreased, while α-synuclein in projections from
distal regions persisted. Toluidine Blue staining of in situ
sections showed that decreased SNCA  levels in mice
treated with SNCA siRNA were not due to neuronal loss
(data not shown).Molecular Neurodegeneration 2008, 3:19 http://www.molecularneurodegeneration.com/content/3/1/19
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Resilience of SNCA knockdown in mice
In order to determine the length of time SNCA expression
can be repressed following siRNA treatment, we infused
SNCA siRNA into the right CA1 of four cohorts. Following
15 days infusion, the first cohort (2 W) was harvested as
above, while the cannulae were removed from the
remaining cohorts which were then allowed to age for 1
week (2 W-1 W), 2 weeks (2 W-2 W), or three weeks (2 W–
3 W) post-infusion. One cannula in the 2 W–3 W group
was loose at the end of the study. This mouse, represented
by a triangle, was included in the data analysis for Figure
3. Following in situ for SNCA, we observed approximately
60% knockdown in SNCA expression in the right CA1 and
cortex compared to the uninjected left side (Figure 3)
which replicated our previous experiments. Additionally,
similar SNCA reductions were observed in the right CA2,
CA3, and dentate gyrus of mice treated with SNCA siRNA
(data not shown). SNCA  levels remained qualitatively
reduced 1 week post-infusion in the dentate gyrus (data
not shown) and 2 weeks post-infusion in the CA1 (Figure
3A), CA2, CA3 (data not shown), and cortex (Figure 3B).
By three weeks post-infusion, SNCA levels in the cortex
(Figure 3B), CA2, CA3, and dentate gyrus (data not
shown) of the siRNA infused side approached control lev-
els. SNCA levels in the right CA1 (Figure 3A), the site of
injection, remained noticeably reduced when compared
to the uninjected control side through three weeks post-
infusion. As in the earlier studies, we saw no impact of
SNCA siRNA on the levels of SNCB at any timepoint (Fig-
ure 3).
The use of naked siRNAs in the brain has recently been
shown be effective against endogenous murine amyloid
precursor protein (APP) [25], dopamine transporter
(DAT), serotonin transporter (SERT) [26-28], and mutant
human huntingtin [29]. The use of RNAi to reduce endog-
enous α-synuclein expression was demonstrated in SH-
SY5Y cells as well as the impact of silencing on dopamine
homeostasis and response to mitochondrial toxins in vitro
[30]. Our study presents the first successful in vivo use of
stabilized naked siRNA against endogenous SNCA and
also demonstrates that a close homologue of the target
gene, SNCB, was not altered by RNA interference with
naked siRNA in the brain. This analysis of SNCB is partic-
ularly important in demonstrating the specificity of the
SNCA siRNA silencing, and in showing that an increase in
SNCB expression does not compensate for a reduction in
its homologue, SNCA. Furthermore, our study also dem-
onstrates that knockdown of SNCA lasted for up to three
weeks post infusion, in the CA1, and that the effect was
not limited to the hippocampus, the immediate site of
delivery, but also diffused into the cortex.
While this study focused on SNCA knockdown in the hip-
pocampus for technical practicalities, it would be of con-
siderable interest to determine if SNCA siRNA would be
efficacious in the SN, given its importance in PD. Future
work aimed at SN delivery and at silencing SNCA in trans-
genic mouse models for human α-synucleinopathy or
toxin models that develop PD like pathology will further
enhance our knowledge on the applicability of naked
siRNA in the brain and importantly on the suitability of
RNA interference of SNCA as a future therapeutic target.
Conclusion
In this study we have characterized naked siRNA duplexes
that actively reduce endogenous SNCA mRNA in vitro and
in vivo. Following in vitro evaluation of nine siRNAs to
assess efficacy, specificity and stability, we selected a can-
didate (Mayo8S2) for in vivo testing. After modification to
complement the murine sequence (Mayo8S2M), we show
that direct infusion of our candidate siRNA into the hip-
pocampi of adult mice resulted in a resilient reduction in
the murine SNCA transcript level around the site of infu-
sion as well as in more distant sites. This approach will
now facilitate a variety of in vivo experiments to tempo-
rally dissect the impact of SNCA up-regulation, aggrega-
tion and Lewy-like pathology, in cellular toxicity and
neurodegeneration. While considerable work is still
needed to optimize delivery, distribution profiles, and sta-
bility of the siRNA before this technique could be applied
in the clinic, our study provides the foundation for such
Table 1: Quantitative densitometry of SNCA in situ hybridization
SNCA densitometry R/L ratio
Brain region PBS (N = 9) Luciferase siRNA (N = 10) SNCA siRNA (N = 11) P-value: SNCA vs. Luciferase P-value: SNCA vs. PBS
Cortex 0.92 (0.82 – 0.98) 0.90 (0.86 – 1.00) 0.27 (0.20 – 0.90) 0.036 0.067
CA1 1.02 (0.98 – 1.14) 0.97 (0.93 – 1.06) 0.35 (0.14 – 0.54) <0.001 <0.001
CA2 1.02 (0.93 – 1.05) 1.01 (0.97 – 1.15) 0.42 (0.19 – 0.62) <0.001 <0.001
CA3 1.15 (0.99 – 1.24) 1.09 (1.01 – 1.15) 0.27 (0.12 – 0.71) <0.001 <0.001
DG 1.02 (0.99 – 1.11) 0.99 (0.94 – 1.04) 0.19 (0.10 – 0.68) 0.008 0.001
Using densitometry to determine efficacy of SNCA siRNA, SNCA expression in the injected (PBS, luciferase siRNA or SNCA siRNA) right side was 
compared to the uninjected left side and compared across treatment groups. P-values were derived from Wilcoxon rank sum test and the sample 
median (25th percentile – 75th percentile) is given.Molecular Neurodegeneration 2008, 3:19 http://www.molecularneurodegeneration.com/content/3/1/19
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studies and offers hope that this technique may eventually
translate into a neuroprotective therapy for α-synuclein-
opathies, including PD, DLB and MSA.
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Complementary positions of the nine siRNA reagents (Mayo 1-Mayo 9) 
in relation to the full length SNCA transcript. [NM_000345.2 – longer 
transcript (isoform NACP140)]. Translation start and stop codons are 
shown in bold.
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Additional file 2
Immunoblot analysis of in vitro screening of SNCA siRNA in BE(2) M17 
human neuroblastoma cells. (A) A typical immunoblot showing EGFP 
and α-tubulin immunoreactivities. Cells were transfected with either 
pEGFP-C1 (vector) or pEGFP-NACP (α-syn) and one of the Mayo1–9 
siRNA reagents or siRNAMr. The three rightmost lanes are no-siRNA 
controls and an untransfected culture. The conjugated EGFP and α-synu-
clein product (EGFP/NACP) is retarded by the additional 140 amino 
acids encoded by the SNCA cDNA. (B) Densitometric analysis of com-
bined data from four blots expressed as a fold value of the no-siRNA con-
trol according to EGFP:α-tubulin ratio. * p < 0.001, t-test, Welch's 
modified t-test was used when variances differed.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
1326-3-19-S2.doc]
Additional file 3
Silencing of endogenous α-synuclein in vitro. (A) qRT-PCR of endog-
enous SNCA transcript from RNA preparations from cells treated with 50 
nM siRNAs (Mayo 2, 7, 8, 9, siRNAMr) for 24 h. Each sample was 
assayed in quadruplicate, and expressed as a fold change from the 
untransfected control. * p < 0.05 t-test, Welch's modified t-test was used 
when variances differed. Error bars = SEM. (B) A typical immunoblot of 
cell extracts following 24 h transfection with 50 nM siRNA. The control 
is treated with transfection reagent alone. The position of a 16 kDa 
marker (lysozyme) is indicated. (C) Densitometric analysis of four inde-
pendent experiments demonstrates significant reduction in the α-synu-
clein immunoreactivity (IR). * p < 0.05; ** p < 0.01 in t-test, Welch's 
modified t-test was used when variances differed. Error bars = SEM.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
1326-3-19-S3.doc]
Additional file 4
Target specificity of candidate siRNA molecules. (A) RNA preparations 
from cells treated for 24 h with 50 nM Mayo2 were analyzed by qRT-
PCR. Although SNCA and SNCB diverge by only four bases within the 
Mayo2 sequence, silencing is specific to SNCA only. (B and C) Co-trans-
fection studies in cells demonstrate that Mayo2 is active against both 
human and mouse SNCA, but human specific Mayo7 and Mayo8 do not 
silence mouse SNCA expression. Error bars = SEM, calculated from three 
independent assays.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
1326-3-19-S4.doc]
Additional file 5
Stabilization of siRNAs was achieved by chemical modifications as shown 
below.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
1326-3-19-S5.doc]
Additional file 6
Species specificity of mouse and human SNCA siRNA. (A) A typical 
immunoblot of total protein extracts from cells co-transfected with plas-
mids conferring expression of EGFP (V; vector) or EGFP-NACP (H = 
human α-synuclein; M = mouse α-synuclein) alone (control) or with 50 
nM of either Mayo8S2 or Mayo 8S2M siRNA. A reprobe of the blot with 
α-tubulin antibody was used to equalize loading levels. (B) Densitometric 
analysis of three independent assays demonstrates that silencing of SNCA 
expression by Mayo8S2 is human specific, and by Mayo8S2M is mouse 
specific. p < 0.01, t-test, Welch's modified t-test was used when variances 
differed. Error bars = SEM. *
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
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